RedHill Biopharma enrols last patient in Phase II irritable bowel syndrome trial

RedHill Biopharma has enrolled the last patient in the Phase II study with Bekinda (RHB-102) 12 mg for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D).

Spotlight

Other News

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More